Cite
Lai LP, Brel V, Sharma K, et al. Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition. SLAS Discov. 2021;26(7):922-932doi: 10.1177/24725552211008853.
Lai, L. P., Brel, V., Sharma, K., Frappier, J., Le-Henanf, N., Vivet, B., Muzet, N., Schell, E., Morales, R., Rooney, E., Basse, N., Yi, M., Lacroix, F., Holderfield, M., Englaro, W., Marcireau, C., Debussche, L., Nissley, D. V., & McCormick, F. (2021). Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition. SLAS discovery : advancing life sciences R & D, 26(7), 922-932. https://doi.org/10.1177/24725552211008853
Lai, Lick Pui, et al. "Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition." SLAS discovery : advancing life sciences R & D vol. 26,7 (2021): 922-932. doi: https://doi.org/10.1177/24725552211008853
Lai LP, Brel V, Sharma K, Frappier J, Le-Henanf N, Vivet B, Muzet N, Schell E, Morales R, Rooney E, Basse N, Yi M, Lacroix F, Holderfield M, Englaro W, Marcireau C, Debussche L, Nissley DV, McCormick F. Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition. SLAS Discov. 2021 Aug;26(7):922-932. doi: 10.1177/24725552211008853. Epub 2021 Apr 24. PMID: 33896272.
Copy
Download .nbib